All Information (Except Text) for S.1803 - MEDS Act115th Congress (2017-2018)
|Sponsor:||Sen. Hatch, Orrin G. [R-UT] (Introduced 09/13/2017)|
|Committees:||Senate - Judiciary|
|Latest Action:||09/13/2017 Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S5483-5484) (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
There is 1 version of this bill. View text
Click the check-box to add or remove the section, click the text link to scroll to that section.
Titles Actions Overview All Actions Cosponsors Committees Related Bills Subjects Latest Summary All Summaries
Actions Overview (1)
|09/13/2017||Introduced in Senate|
09/13/2017 Introduced in Senate
All Actions (1)
|09/13/2017||Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S5483-5484)|
Action By: Senate
09/13/2017 Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S5483-5484)
|Sen. Schatz, Brian [D-HI]*||09/13/2017|
|Sen. Gardner, Cory [R-CO]*||09/13/2017|
|Sen. Coons, Christopher A. [D-DE]*||09/13/2017|
|Sen. Tillis, Thom [R-NC]*||09/13/2017|
|Sen. Gillibrand, Kirsten E. [D-NY]||10/02/2017|
|Sen. Kaine, Tim [D-VA]||11/13/2017|
|Sen. Klobuchar, Amy [D-MN]||04/25/2018|
|Committee / Subcommittee||Date||Activity||Reports|
|Senate Judiciary||09/13/2017||Referred to|
Subject — Policy Area:
One Policy Area term, which best describes an entire measure, is assigned to every public bill or resolution.
Latest Summary (1)
Introduced in Senate (09/13/2017)
Marijuana Effective Drug Studies Act of 2017 or the MEDS Act
This bill amends the Controlled Substances Act to establish a new, separate registration process to facilitate research involving marijuana and the commercial production of drugs made from marijuana.
Specifically, the bill requires the Drug Enforcement Administration to register manufacturers and distributors to supply marijuana: (1) for use in research, and (2) for the commercial production of approved drugs containing or derived from marijuana.